19/03/26

Growing a biotech company takes more than great science, strong IP, and a talented team. To truly bring your innovation to patients, partnering with a pharmaceutical company can be a critical step. The right collaboration can give you access to expertise, (non-dilutive) funding, and networks that are otherwise hard to tap into.

In this workshop, Johnson & Johnson’s team will share practical insights from their experience in building partnerships with early-stage companies. You’ll hear directly from dealmakers and innovation scouts about how they evaluate opportunities, what they look for in potential partners, and the steps involved in moving from first conversation to a signed agreement.

Our goal is to help you understand what makes a partnership successful and how you can position your company to be “partner-ready” sooner.

We’ll discuss:

How to identify pharma companies that align with your strategy—and what they’re really looking for.
How to tailor your non-confidential information to resonate with pharma decision-makers.
What to expect in the process: from first meeting to diligence, term sheet, and negotiations.
How to maintain and grow the relationship, if the deal is signed as well as if the deal does not progress.

The program is tailored to founders, C-level executives, and business developers from biotech and life sciences startups developing pharmaceutical assets or enabling technologies (excluding vaccines and diagnostics). It will also have relevant insights for VCs, TTOs, and incubators. Please register via the website.

door Idalia Dlugosz